Conference Track

Clinical Pharmacology and Adverse Events

Source: CCO Official Conference Coverage of the 2006 International AIDS Conference

Capsule Summaries

Pharmacokinetic Analysis Suggests Brecanavir Coadministration Feasible With Lopinavir/Ritonavir or Atazanavir, but Not Tipranavir/Ritonavir
No Darunavir Exposure-Efficacy and Exposure-Safety Relationships Observed in POWER 3 Study
Pharmacokinetic Study of Coadministration of Etravirine (TMC125) and Darunavir (TMC114)/Ritonavir in Healthy Volunteers
Continuation of NRTIs 1 Week Beyond Nevirapine Discontinuation Appropriate for Structured Treatment Interruption in African Patients
Hepatotoxicity, Other Severe Adverse Events Occur With Nevirapine-Based HAART in Pregnant Mozambican Women With CD4+ Cell Counts < 350 cells/mm³
DART Study: Low Rate of Severe Renal Impairment in Antiretroviral-Treated Patients in Resource-Limited Settings

Expert Analysis

Clinical Pharmacology and Adverse Events

Faculty:
Terrence F. Blaschke, MD Charles Boucher, MD, PhD William G. Powderly, MD

Learning Objectives

Upon completion of this activity, participants should be able to:

Review data related to pharmacokinetic interactions among antiretroviral agents
Discuss recommendations on how to safely discontinue nevirapine when stopping therapy
Recount data on adverse events associated with antiretroviral agents

CME CREDIT INFORMATION

Release Date: 11/13/06

Expiration Date: 11/12/07

Physicians: maximum of 0.75 AMA PRA Category 1 Credit(s)™

Pharmacists: 1 contact hour (0.1 CEUs)

Registered Nurses: 1 Nursing CE credit

Status: Please log in to view status

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.